XenoTherapeutics Overview

  • Founded
  • 2016
  • Status
  • Private
  • Employees
  • 10
  • Latest Deal Type
  • Grant
  • Investors
  • 3

XenoTherapeutics General Information


Operator of a gene therapy company intended to develop personalized cells, tissues, and organs for transplantation. The company's first product is derived from genetically engineered, immune-corrected pigs, enabling victims with severe and extensive burns in Phase I clinical trial to access an affordable, safe and plentiful treatment whenever is necessary.

Contact Information

Ownership Status
Privately Held (no backing)
Financing Status
Primary Industry
Therapeutic Devices
Other Industries
Primary Office
  • PO Box 1362
  • Londonderry, NH 03053
  • United States
+1 (617) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

XenoTherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Grant Completed Startup
2. Grant 27-Jan-2017 0000 Completed Startup
1. Grant 19-May-2016 Completed Startup
To view XenoTherapeutics’s complete valuation and funding history, request access »

XenoTherapeutics Comparisons

HQ Location
Total Raised
Post Valuation
Last Financing Details
Operator of a gene therapy company intended to develop personalized cells, tissues, and organs for transplantation. The
Therapeutic Devices
Londonderry, NH
10 As of 2020


eprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
0000 000000000
Stockholm, Sweden
00 As of 0000
0000000000 0 0000


elit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, su
Cambridge, MA
00 As of 0000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

XenoTherapeutics Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ITBMed Venture Capital-Backed Stockholm, Sweden 00 0000 0000000000 0 0000
00000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
000000 00000000000 Formerly VC-backed Silver Spring, MD 000 00000 000000 - 000 00000
000000000 Corporation
To view XenoTherapeutics’s complete competitors history, request access »

XenoTherapeutics Executive Team (5)

Name Title Board Seat Contact Info
Curtis Cetrulo Jr. President of the Board
Krysta Moulton Chief Financial Officer & Financial Controller
Jon Adkins Co-Founder & Chief Sales Officer
William Deacon Vice President of Board
Paul Holzer Ph.D Co-Founder & Chief Executive Officer
To view XenoTherapeutics’s complete executive team members history, request access »

XenoTherapeutics Board Members (3)

Name Representing Role Since
Michael Yaremchuk XenoTherapeutics Trustee of Board 000 0000
Paul Barrett XenoTherapeutics Chairman 000 0000
You’re viewing 2 of 3 board members. Get the full list »

XenoTherapeutics Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

XenoTherapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
John Flatley Company Corporation 000 0000 000000 0
MassChallenge Accelerator/Incubator 000 0000 000000 0
Columbia Technology Ventures University Minority 000 0000 000000 0
To view XenoTherapeutics’s complete investors history, request access »